| Ytd | -44.84% | |
| 1y | -16.49% |
| Open | 5.52 | Prev Close | 5.53 | Low | 5.44 | High | 5.75 | Mkt Cap | 220.77M |
| Vol | 209.37K | Avg Vol | 355.24K | EPS | -3.96 | P/E | N/A | Forward P/E | -5.54 |
| Beta | -0.27 | Short Ratio | 11.43 | Inst. Own | 80.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 6.83 | 200-d Avg | 9.22 | 1yr Est | 26.43 |
TRDA News
Entrada Therapeutics is rated Buy with a $8.50 fair value, offering ~52% upside from $5.61, driven b
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support p
BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc. (NASDAQ: TRDA) during the undefin
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the ana
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELE
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy a
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committ
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 --
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Entrada Ther
LOS ANGELES, May 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights lit
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. See wh
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Entrada Therapeutics (NASDAQ:TRDA)
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US
Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despit
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.95) per share which beat the ana
Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outper
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the ana
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA)
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 ---- Co
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Entrada Therapeutics (NASDAQ:TRDA)
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-20
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the a
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the a
Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company anno
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announce
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
During Friday's morning session, 234 stocks hit new 52-week lows.